Skip to main content

Specific Antibody Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
Diagnosis of SPAD using immunization with PPV23N/A1 trial
Active Trials
NCT05664035Recruiting99Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
TakedaDiagnosis of SPAD using immunization with PPV23

Clinical Trials (1)

Total enrollment: 99 patients across 1 trials

NCT05664035TakedaDiagnosis of SPAD using immunization with PPV23

Frequency of SPAD in Adult Patients

Start: Mar 2023Est. completion: Jun 202699 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 99 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specific Antibody Deficiency | Pipeline & Competitive Landscape | Formulate